MedPath

Tagged News

FDA Recalls Six Acne Products After Testing Reveals Benzene Contamination Above Safety Limits

  • The FDA announced voluntary recalls of six popular acne products containing benzoyl peroxide after testing revealed elevated benzene levels above the conditional limit of two parts per million.
  • Independent testing by Valisure laboratory found that benzoyl peroxide breaks down into the carcinogen benzene over time, with some products containing levels as high as 35 ppm.
  • Of 95 acne products tested by the FDA, more than 90 percent had undetectable or extremely low benzene levels, but six products required recall due to elevated contamination.
  • Researchers emphasize that benzene exposure from multiple sources creates cumulative cancer risk, particularly concerning for products applied directly to skin.

FDA Recalls 7,107 Bottles of Generic Duloxetine Over Carcinogenic Chemical Contamination

  • The FDA issued a Class II recall for 7,107 bottles of generic duloxetine antidepressant due to contamination with N-nitroso-duloxetine, a toxic chemical suspected of causing cancer.
  • The recalled medication was manufactured by Towa Pharmaceutical Europe and distributed nationally, affecting 500-count delayed-release 20mg capsules with lot number 220128 and December 2024 expiration.
  • Patients are advised not to stop taking their medication abruptly but should consult healthcare professionals about the best course of action for their treatment.
  • The recall reflects increased FDA testing for nitrosamine impurities in medications, with the agency working internationally to establish safer daily intake limits for these chemicals.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.